000177926 001__ 177926
000177926 005__ 20240229133755.0
000177926 0247_ $$2doi$$a10.1007/s00432-021-03865-3
000177926 0247_ $$2pmid$$apmid:34874489
000177926 0247_ $$2ISSN$$a0084-5353
000177926 0247_ $$2ISSN$$a0171-5216
000177926 0247_ $$2ISSN$$a0943-9382
000177926 0247_ $$2ISSN$$a1432-1335
000177926 0247_ $$2altmetric$$aaltmetric:118339652
000177926 037__ $$aDKFZ-2021-02948
000177926 041__ $$aEnglish
000177926 082__ $$a610
000177926 1001_ $$0P:(DE-He78)a4307287511137778efe28e651f9f245$$aScherer-Trame, Sophie$$b0$$eFirst author$$udkfz
000177926 245__ $$aQuality of life, distress, and posttraumatic growth 5 years after colorectal cancer diagnosis according to history of inpatient rehabilitation.
000177926 260__ $$aHeidelberg$$bSpringer$$c2022
000177926 3367_ $$2DRIVER$$aarticle
000177926 3367_ $$2DataCite$$aOutput Types/Journal article
000177926 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1665050052_20167
000177926 3367_ $$2BibTeX$$aARTICLE
000177926 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000177926 3367_ $$00$$2EndNote$$aJournal Article
000177926 500__ $$a#EA:C120#LA:C070#LA:C120# / 2022 Nov;148(11):3015-3028
000177926 520__ $$aIn Germany, almost every other colorectal cancer (CRC) patient undergoes inpatient cancer rehabilitation (ICR), but research on long-term outcomes is sparse. We aimed to assess health-related quality of life (HRQOL), distress, and posttraumatic growth among former rehabilitants and non-rehabilitants as well as respective differences and to estimate disease-related quality of life deficits in both groups.HRQOL (EORTC-QLQ-C30/CR29), distress (QSC-R10), and posttraumatic growth (PTGI) were assessed according to past ICR in patients 5-year post-CRC-diagnosis in the German DACHS study. Least square mean differences in HRQOL scores and elevated distress levels (QSC-R10 > 14 points) by ICR were estimated by confounder-adjusted linear and logistic regression, respectively. Differences in PTGI scales were tested for statistical significance. EORTC-QLQ-C30 reference scores from population controls were accessed from the LinDE study to estimate disease-related deficits in both treatment groups.49% of the included 1906 CRC survivors had undergone ICR. Rehabilitants reported lower HRQOL scores than non-rehabilitants in several dimensions of the EORTC-QLQ-C30/CR29. Differences were pronounced among younger survivors (< 70 years). In younger survivors, past ICR also predicted elevated distress. However, rehabilitants showed higher posttraumatic growth. When compared to 934 population controls, non-rehabilitants and older rehabilitants reported HRQOL scores (EORTC-QLQ-C30) similar to controls except higher levels of bowel dysfunctions, whereas younger rehabilitants experienced deficits regarding most scales (13/15).Our findings suggest a high disease burden 5 years after diagnosis in particular among younger CRC survivors who had undergone ICR. Observed HRQOL deficits are possibly linked to the initial indication for ICR and rehabilitants may benefit from effective follow-up concepts after ICR.
000177926 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000177926 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000177926 650_7 $$2Other$$aCancer survivorship
000177926 650_7 $$2Other$$aColorectal cancer
000177926 650_7 $$2Other$$aDistress
000177926 650_7 $$2Other$$aHealth-related quality of life
000177926 650_7 $$2Other$$aInpatient rehabilitation
000177926 650_7 $$2Other$$aPosttraumatic growth
000177926 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b1$$udkfz
000177926 7001_ $$0P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aKoch-Gallenkamp, Lena$$b2$$udkfz
000177926 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b3$$udkfz
000177926 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b4$$udkfz
000177926 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b5$$udkfz
000177926 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b6$$eLast author$$udkfz
000177926 773__ $$0PERI:(DE-600)1459285-X$$a10.1007/s00432-021-03865-3$$n11$$p3015-3028$$tJournal of cancer research and clinical oncology$$v148$$x0171-5216$$y2022
000177926 909CO $$ooai:inrepo02.dkfz.de:177926$$pVDB
000177926 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a4307287511137778efe28e651f9f245$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000177926 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000177926 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000177926 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000177926 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000177926 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000177926 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000177926 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000177926 9141_ $$y2021
000177926 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-31$$wger
000177926 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-31
000177926 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-31
000177926 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-31
000177926 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-17
000177926 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-17
000177926 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-17
000177926 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-17
000177926 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-17
000177926 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-17
000177926 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CANCER RES CLIN : 2021$$d2022-11-17
000177926 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-17
000177926 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-17
000177926 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-17
000177926 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000177926 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000177926 9201_ $$0I:(DE-He78)M110-20160331$$kM110$$lM110 Epidemiologisches Krebsregister Baden-Württemberg$$x2
000177926 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x3
000177926 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x4
000177926 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x5
000177926 980__ $$ajournal
000177926 980__ $$aVDB
000177926 980__ $$aI:(DE-He78)C120-20160331
000177926 980__ $$aI:(DE-He78)C070-20160331
000177926 980__ $$aI:(DE-He78)M110-20160331
000177926 980__ $$aI:(DE-He78)C071-20160331
000177926 980__ $$aI:(DE-He78)C020-20160331
000177926 980__ $$aI:(DE-He78)HD01-20160331
000177926 980__ $$aUNRESTRICTED